BRCA1 and ovarian cancer: Discovery of the breast cancer-predisposition genes BRCA1 and BRCA2 has enabled us to identify carriers accurately, to target the reduction of risk of breast and ovarian cancers in carriers, and to develop a new generation of targeted therapies (PARP inhibitors) [1].